[ET Net News Agency, 6 May 2021] Venus Medtech (Hangzhou) Inc. (02500) said the group
has resolved to invest in Valgen Holding Corporation, an innovative medical device company
registered in the Cayman Islands.
The move is expected to improve Venus's strategic layout in the field of structural
heart disease treatment and grasp development opportunities brought about by the
transcatheter interventional therapy technologies.
ValgenMed is committed to providing systematic solutions for diseases such as mitral
regurgitation and tricuspid regurgitation. ValgenMed has developed MitralStitch, the first
device in China for transcardial interventional treatment of mitral regurgitation,
DragonFly-M, China's first femoral vein mitral valve repair device and DragonFly-T,
China's first femoral vein tricuspid valve repair device, of which MitralStitch and
DragonFly-M have entered pre-marketing registration clinical study stage and DragonFly-T
has entered exploratory clinical study stage. (KL)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02500 VENUS MEDTECH-B
Nominal 
5.620 0.000 (0.000%) Disclosure of Interest
06/05/2021 09:16
Venus Medtech (02500) to invest in medical device company
| Remark: | Real time quote last updated: 19/04/2024 15:47 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |